David Gooray, MD
Cardiovascular Disease · Largo, MDNPI 1720070261
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $283,390 of the $332,653 with a category attached, or 85.2%. 33 manufacturers reported payments, led by Boehringer Ingelheim at 37.1% of the total. Reporting peaked in 2019 at $151,262 and has fallen 87.1% since, to $19,477 in 2025. Among cardiovascular disease clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 754 payments — averaging $441.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$124K
- Lilly USA, LLC$115K
- Novartis$69K
- Bayer$10K
- Alnylam Pharmaceuticals Inc.$5K
- Abbott$2K
- plus $9K from 27 others
What the payments were for
- Consulting fees$8,7153%
- Speaking & faculty fees$283,39085%
- Travel & lodging$25,7888%
- Food & beverage$14,4994%
- Education$2600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 153 | $123,527 |
| Lilly USA, LLC | 142 | $115,025 |
| Novartis | 115 | $68,593 |
| Bayer | 34 | $10,056 |
| Alnylam Pharmaceuticals Inc. | 21 | $4,677 |
| Abbott | 17 | $1,730 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $1,514 |
| Atricure, Inc. | 10 | $1,483 |
| E.r. Squibb & Sons, L.L.C. | 41 | $848 |
| AstraZeneca | 32 | $802 |
| Merck | 34 | $775 |
| Novo Nordisk | 20 | $679 |
| Actelion Pharmaceuticals US, Inc. | 12 | $448 |
| Boston Scientific | 9 | $441 |
| Gilead | 37 | $402 |
| Corcept Therapeutics | 4 | $197 |
| Scpharmaceuticals Inc. | 7 | $170 |
| GSK | 7 | $153 |
| Lexicon Pharmaceuticals, Inc. | 7 | $141 |
| Azurity Pharmaceuticals, Inc. | 11 | $136 |
| Pfizer | 7 | $135 |
| Portola Pharmaceuticals, LLC | 1 | $126 |
| Bridgebio Pharma, Inc. | 1 | $109 |
| Amarin Pharma, Inc. | 5 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $92 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $54 |
| Ironwood Pharmaceuticals, Inc | 3 | $51 |
| AbbVie | 3 | $50 |
| Johnson & Johnson(2 entities) | 2 | $42 |
| Arbor Pharmaceuticals, Inc. | 3 | $36 |
| Intercept Pharmaceuticals, Inc. | 1 | $25 |
| Mannkind Corporation | 1 | $22 |
| Heartflow, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$332,653 in reported general payments places this provider in the 95th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 226 | $284,772 |
| JardianceEmpagliflozin | 217 | $216,928 |
| EliquisApixaban | 160 | $173,467 |
| OzempicSemaglutide | 61 | $105,297 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $57,483 |
| TrulicityDulaglutide | 30 | $51,576 |
| FarxigaDapagliflozin Propanediol | 32 | $40,049 |
| VerquvoVericiguat | 27 | $36,610 |
| VascepaIcosapent Ethyl | 44 | $34,784 |
| BrilintaTicagrelor | 27 | $26,989 |
| KerendiaFinerenone | 18 | $20,301 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $13,418 |
| Ranolazine ErRanolazine | 60 | $10,016 |
| Nicardipine Hcl | 15 | $9,442 |
| Eplerenone | 58 | $8,639 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $68,593 | $284,772226 claims |
| Boehringer IngelheimJardiance | $123,527 | $216,928217 claims |
| PfizerEliquis | $135 | $173,467160 claims |
| Novo NordiskOzempic | $679 | $105,29761 claims |
| AstraZenecaFarxiga, Brilinta, Breztri Aerosphere | $802 | $80,45674 claims |
| GSKTrelegy Ellipta | $153 | $57,48354 claims |
| Lilly USA, LLCTrulicity | $115,025 | $51,57630 claims |
| MerckVerquvo | $775 | $36,61027 claims |
| BayerKerendia | $10,056 | $20,30118 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $36 | $14,85224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 507 cardiovascular disease providers in Maryland.
Other cardiovascular disease in Largo
- Navin KapurBaltimore$1.5M
- Michael BlahaBaltimore$609K
- Sanjay RajagopalanBaltimore$521K
- Allen TaylorN Bethesda$456K
- Erin MichosBaltimore$257K
- Seth MartinBaltimore$166K
- Erika FellerBaltimore$121K
- Mark HaigneyBethesda$121K
- Charles CummingsBaltimore$114K
- John RickardBaltimore$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.